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p53 is a key tumor suppressor protein that has numerous functions. Its primary mode of action has
generally been ascribed to the induction of cell-cycle arrest, apoptosis, or senescence upon stress.
Li et al. challenge this dogma with evidence that all three of these programs are dispensable for
p53’s tumor suppressive role.Over the past 30 years, the p53 tumor
suppressor has been subjected to intense
scrutiny, with a bewildering and ever-
increasing number of functions and activi-
ties attributed to it. A general consensus
has emerged, however, that the key func-
tion of p53 in preventing tumor develop-
ment is the ability to inhibit the outgrowth
of inchoate cancers. An elegant and
simple model built on numerous studies
dictates thatmanyof the stress signals en-
countered by nascent tumor cells (such as
oncogene activation, telomere erosion,
hypoxia, and genotoxic damage) lead to
the activation of p53, which in turn drives
the expression of genes that coordinate
programs of three key responses: cell-
cycle arrest, apoptosis, and senescence
(Vousden and Prives, 2009) (Figure 1).
The cell exposed to oncogenic stress is
therefore prevented from further prolifera-
tion and tumor development avoided.
So the publication of a paper entitled
‘‘Tumor Suppression in the Absence
of p53-Mediated Cell-Cycle Arrest,
Apoptosis, and Senescence’’ will cause
some excitement and possibly a degreeof consternation in the field (Li et al.,
2012). Has all our thinking so far been
misled? If these three activities are not
required for p53 to suppress tumor devel-
opment, then what is? Are the other activ-
ities of p53—that have so far been
thought of rather as support roles—really
the key to cancer prevention? Certainly
this very interesting study will generate
much attention.
p53 is a transcription factor and acts
primarily to regulate gene expression.
Although much of the regulation of p53
activity is determined by the stability of
the p53 protein, a large number of post-
translational modifications on p53 also
function to regulate DNA binding and
engagement with the transcriptional
machinery (Dai and Gu, 2010). In general,
events such as phosphorylation or acety-
lation on individual sites have rather
modest effects on p53 activity, and iden-
tifying key modifications that are critical
for p53 function has proven to be rather
frustrating. Now Li et al. provide evidence
that a p53 protein mutated in three of the
lysines that are subject to acetylation inthe wild-type protein (the 3KR mutant)
fails to induce cell-cycle arrest, apoptosis,
or senescence in mice (supporting results
from the same group showing acetylation
is important for these three p53 functions
in cells)—but yet retains the ability to
protect mice from tumor development.
Maybe this should not be so surprising;
indeed several previous studies have
hinted that not all these responses are
always required (Bieging and Attardi,
2012). Loss of the primary mediators of
p53-induced cell-cycle arrest (p21) or
apoptosis (PUMA) clearly do not to lead
to tumor susceptibility in the same way
as loss of p53. Other p53 mutants that
are defective in apoptosis or cell-cycle
arrest have been shown to retain tumor
suppressor activity (Brady et al., 2011;
Liu et al., 2004), although in these cases
at least one of the ‘‘big three’’ responses
was retained. Intriguingly, the p53-medi-
ated induction of arrest and apoptosis
that is seen in the immediate response
following irradiation was shown to be
irrelevant for suppression of radiation-
induced lymphoma (Christophorou et al.,49, June 8, 2012 ª2012 Elsevier Inc. 1183
Figure 1. Cell-Cycle Arrest, Senescence, and Apoptosis are Dispensable for p53’s Tumor
Suppressive Potential
Mice with wild-type p53 are capable of inducing many target genes, including p21, BAX, PUMA, and
NOXA to drive cell-cycle arrest, apoptosis and senescence. p53 also positively or negatively regulates the
expression of genes like TIGAR, GLS2 and GLUT3 that control metabolism and antioxidant defenses.
Complete loss of p53 results in a defective ability to engage these programs and results in spontaneous
development of lymphomas in mice. Mutating three lysines to arginine (K117R, K161R, K162R) to inhibit
acetylation at these sites renders p53 incapable of inducing cell-cycle arrest, apoptosis, and senescence.
Surprisingly this does not change p53’s ability to regulate the expression of metabolic target genes or
prevent its tumor suppressive action.2006). Finally, reactivation of p53 in estab-
lished tumors results in tumor regression
that is accompanied by either apoptosis
or senescence, depending on the tumor
type (Ventura et al., 2007). Taken together,
these studies have shown that cell-cycle
arrest, senescence, and apoptosis are
not all necessary for tumor suppression
but generally suggested that at least one
or other of these responses would be
important. Li et al. now show that none of
them is actually required—at least to
restrain lymphoma development.
Delving into the exact nature of the
defect in this mutant, the authors show
that although the 3KR mutant retains
DNA binding activity, there is a differential
loss of transcriptional function, so that
certain key mediators of the cell-cycle
arrest or apoptotic response to p53—
such as p21 or PUMA—cannot be in-
duced by the lysine mutant. In contrast,
other transcriptional targets of p53,
including MDM2, remain as responsive
as to thewild-type p53protein. Differential
regulation of transcriptional targets by
different p53 mutants has been described
in many previous studies, and can reflect
a multitude of defects, including altered
DNA binding activity and changes in the
ability to engage with critical transcrip-1184 Cell 149, June 8, 2012 ª2012 Elsevier Intional cofactors or the basic transcrip-
tional machinery.
So the main question to arise from
these results must be, if not cell-cycle
arrest, apoptosis, or senescence, what
is p53 doing? The paper from Li et al.
goes on to throw some light on this, by
showing that the target genes that remain
responsive to the lysine mutant of p53
include those related to the regulation of
energy metabolism and antioxidant func-
tion. Specifically, the ability of 3KR to
activate GLS2 (the mitochondrial gluta-
minase) and TIGAR (a fructose2,6 bis-
phosphatase) expression are highlighted
in the study, although this p53 mutant
is certain to retain much broader tran-
scriptional function in both promoting
and inhibiting gene expression—as illus-
trated by the continued ability of the
mutant p53 to restrain expression of the
GLUT3 glucose transporter. TIGAR (Ben-
saad et al., 2006) and GLS2 (Suzuki
et al., 2010) contribute to what have—until
now—been much less well-studied func-
tions of p53 in modulating mitochondrial
respiration and limiting both glycolysis
and levels of reactive oxygen species
(ROS). These functions of p53 help to
oppose the Warburg effect and protect
cells from oxidative stress—with loss ofc.p53 shifting cells to adopt aerobic glycol-
ysis so commonly seen in cancers (Puzio-
Kuter, 2011). Intriguingly, mice expressing
the 3KR mutant retain the ability to
regulate glucose uptake, glycolysis and
ROS levels—strongly suggesting that
these activities may be key to the ability
of p53 to limit cancer progression.
The role of increased glycolysis and
ROS in cancer progression is not com-
pletely clear—and the concept that ROS
can contribute to cancer progression is
balanced by numerous studies showing
that increased ROS can also be tumor
suppressive. Nevertheless, when consid-
ering these responses in the context of
p53, it seems likely that they are important
components of the tumor suppressor
arsenal. Clearly it remains possible that
there are other functions of p53 (including
the regulation of other target genes) that
are retained in the lysine mutant—and
these may be the critical components in
tumor suppression. A careful analysis of
the transcriptional program regulated by
wild-type and the mutant p53 proteins
will be extremely informative.
More directed studies to examine
specifically the glycolytic and antioxidant
functions of p53 would also be needed
to fully verify their importance. However,
this may also be less facile than initially
expected. Although the regulation of
genes like GLS2 and TIGAR by p53 could
help prevent cancer development, it has
also been suggested that expression of
such proteins uncoupled from p53 could
ultimately assist in tumor development,
again underlining the paradox that modu-
lation of glycolysis or ROS could both
enhance and prevent cancer progression
depending on context and level. But the
identification of the responses that are
truly crucial for p53-driven tumor sup-
pression will pave the way for the devel-
opment of new therapeutic approaches
based on the modulation of these path-
ways, rather than the regulation of p53
itself. Given that over half of all human
cancers have mutations in p53, the possi-
bility of targeting cancers downstream of
the defect in p53 is extremely attractive.REFERENCES
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A variant neoplastic line of human pluripotent stem cell (hPSC) displays unique tumorigenic
properties, including enhanced self-renewal and survival, and aberrant blockade in differentiation.
Sachlos et al. adopted a neoplastic hPSC differentiation platform to screen small molecules that
selectively induce differentiation of cancer stem cells.Recent studies support a hypothesis in
which subpopulations of tumor cells,
tumor initiating cells (TICs), drive tumori-
genesis and give rise to a large population
of differentiated progenies that make up
most of a tumor. Although conventional
chemotherapies reduce the bulk of the
tumor by effectively eliminating highly
proliferative cancer cells, refractory TICs
allow tumors to recur and thus account
for many treatment failures. The drug
resistance of TICs may be due to their
restricted cell cycle and quiescence;
higher expression of drug pumps; and/or
enhanced antioxidative, antiapoptotic,
DNA repair, and self-renewal mecha-
nisms, many of which are also shared by
tissue-specific normal stem cells. Conse-
quently, differentially targeting TICs, while
sparing normal stem cells, is a major
challenge. However, one strategy might
address that challenge. TICs with onco-
genic molecular alterations may be more
addicted to those above enhanced stemcell mechanisms and therefore targeting
such deregulation may sensitize TICs to
treatments (Frank et al., 2010). For
example, shifting enhanced self-renewal
to the normal level may effectively render
TICs more susceptible to conventional
therapy.
Several studies used chemical genetics
approaches tomodel the differentiation of
stem cells and TICs. Chemical libraries
were screened in hESCs (Desbordes
et al., 2008) or cancer cells with certain
stem-like properties (Gupta et al., 2009)
to identify compounds that maintain or
inhibit their self-renewal, providing tools
to interrogate underlying mechanisms.
However, drug discovery for differentially
targeting TICs (Shen et al., 2004) has
been hindered by difficulties in homoge-
nously expanding and maintaining rare
TICs in vitro (Figure 1A). This problemwas
addressed by developing specific condi-
tions for stably expanding certain subpop-
ulation of TICs (Pollard et al., 2009).In an interesting report published in this
issue of Cell, Sachlos et al. (2012) provide
another attractive approach. They interro-
gated neoplastic human pluripotent stem
cell (hPSC) as a human TIC surrogate for
high-content screening of differentiation
inducing agents (Figure 1B). Compounds
identified with this model were further
shown to selectively decrease the number
of human CD33+ hCD45+ acute myeloid
leukemia (AML) cells in a xenotransplanta-
tion model. This demonstrates the feasi-
bility of finding therapeutic candidates
for differentially targeting TIC differentia-
tion and therapeutic potentials of such
strategy for treating cancer.
Neoplastic hPSC is a culture-adapted
variant hESC line (Werbowetski-Ogilvie
et al., 2009) with subkaryotypic abnormal-
ities that exhibits acquired tumorigenic
features, including enhanced self-renewal
with reduced growth factor dependence
and blocked differentiation. Its FGFR1
and IGFR1 coexpression pattern is similar49, June 8, 2012 ª2012 Elsevier Inc. 1185
